Autolus Therapeutics plc
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
AUTL$1.320.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for the years ended
Consolidated Statements of Cash Flows
(In thousands)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(220,662) | $(208,383) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation on property and equipment | 7,554 | 6,565 |
| Amortization of intangible assets | 162 | — |
| Loss on disposal of property and equipment | 223 | 3,791 |
| Share-based compensation net of amounts capitalized | 15,472 | 11,204 |
| Interest expense accrued on liabilities related to future royalties and milestones, net | 8,867 | 44,999 |
| Accretion of available-for-sale securities | (1,251) | — |
| Foreign exchange differences | 1,898 | (7,604) |
| Non-cash operating lease expense | 4,716 | 4,058 |
| Loss on termination of operating lease | 176 | 95 |
| Impairment of operating lease right-of-use assets and related property and equipment | 414 | 382 |
| Deferred income tax | (185) | (986) |
| Changes in operating assets and liabilities | ||
| (Increase) decrease in prepaid expenses and other current assets | (33,524) | 10,695 |
| Decrease in prepaid expenses and other non-current assets | 938 | 1,726 |
| Increase in inventories, net | (4,229) | — |
| Decrease in long-term deposits | 5 | 937 |
| Increase (decrease) in accounts payable | 1,590 | (509) |
| Increase in accrued expenses and other liabilities | 11,934 | 998 |
| Decrease in operating lease liability | (369) | (13,555) |
| Net cash used in operating activities | (206,271) | (145,587) |
| Cash flows from investing activities: | ||
| Acquisition of property and equipment | (22,075) | (10,986) |
| Acquisition of intangibles assets | (12,744) | — |
| Investment in marketable securities: available-for-sale debt securities | (359,733) | — |
| Net cash used in investing activities | (394,552) | (10,986) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of ordinary shares | 549,977 | — |
| Proceeds from exercise of share options | 602 | 27 |
| Proceeds from liabilities related to future royalties and milestones, net | 70,000 | — |
| Payments of equity issuance costs | (29,360) | (910) |
| Payments of issuance costs related to the liabilities related to future royalties and milestones, net | (1,665) | — |
| Net cash provided by (used in) financing activities | 589,554 | (883) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (261) | 15,030 |
| Net decrease in cash, cash equivalents and restricted cash | (11,530) | (142,426) |
| Cash, cash equivalents and restricted cash, beginning of period | 240,335 | 382,761 |
| Cash, cash equivalents and restricted cash, end of period | $228,805 | $240,335 |
Consolidated Statements of Cash Flows
(In thousands)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental cash flow information | ||
| Cash paid for income taxes | $(2,391) | $(551) |
| Unrealized gains on marketable securities: available-for-sale debt securities | $1,251 | $— |
| Supplemental non-cash flow information | ||
| Property and equipment purchases included in accounts payable or accruedexpenses | $1,793 | $433 |
| Leased assets terminated and obtained in exchange for operating lease liabilities, net | $(975) | $3 |
| Leased assets obtained in exchange for operating lease liabilities | $1,694 | $41,148 |
| Capitalized share-based compensation, net of forfeitures | $3 | $46 |
| Capitalized implementation costs included in accrued expenses | $816 | $564 |
| Issuance costs included in accounts payable and accrued expenses | $— | $272 |
| Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets: | ||
| Cash and cash equivalents | $227,380 | $239,566 |
| Restricted cash | $1,425 | $769 |
| Total cash, cash equivalents and restricted cash | $228,805 | $240,335 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.